It is concluded that EAM-2201 has the probable to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and it is evaluated in pooled human liver microsomes. The computed data are in comparison With all the offered initially theory